NCT05198245 is a clinical trial of Rimegepant in Migraine, sponsored by Pfizer.

Who is sponsoring NCT05198245?

NCT05198245 is sponsored by Pfizer.

What drugs are being tested in NCT05198245?

Interventions in NCT05198245: Rimegepant, Various, No intervention.

Is NCT05198245 still recruiting?

NCT05198245 is currently active, enrolled. Last updated 8 January 2026.

Last reviewed 2026-01-08 · How we verify

NCT05198245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

Active, enrolled Last updated 8 January 2026

What this trial tests

trial testing Rimegepant in Migraine in 1 participant. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 December 2021

Primary endpoint
17 April 2028

17 April 2028

Quick facts

Lead sponsor	Pfizer
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1
Start date	15 December 2021
Primary completion	17 April 2028
Estimated completion	17 April 2028
Sites	1 location across United States

Drugs / interventions tested

Rimegepant (rimegepant) — full drug profile →
Various (various) — full drug profile →
No intervention

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Pfizer — full company profile →

Who can join

Adults 16 to 49, female only, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Gepants - a long way to cure: a narrative review.
Altamura C, Brunelli N, Marcosano M, Fofi L, et al · · 2022 · cited 32× · PMID 35650458 · DOI 10.1007/s10072-022-06184-8
Update on gepants for the treatment of chronic migraine.
Aoh Y, Hou TW, Yang CC, Chang CM, et al · · 2024 · cited 2× · PMID 38349136 · DOI 10.1097/jcma.0000000000001070

Verify or expand the search:

Other trials of Rimegepant

Trials testing the same drug.

NCT06999252 — Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients · Phase 2 · not yet recruiting
NCT06985342 — Acute Migraine Treatment in the ED With Gepants · Phase 4 · recruiting
NCT06992674 — The R-E-V-I-V-A-L Study · Phase 2 · active not recruiting
NCT06748664 — A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment · Phase 2 · not yet recruiting
NCT06641466 — A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual · Phase 3 · recruiting

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05198245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 8 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05198245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing